Methylene Blue (low-dose)
Research Reliability -
A century-old dye repurposed at very low doses as a mitochondrial electron carrier and emerging cognitive compound.
Appetite
Mood
Sleep
Methylene Blue (low-dose)
Description
Methylene blue has been used clinically since the early 1900s, but at very low ("low-dose") amounts it acts as an alternative electron carrier in the mitochondrial electron transport chain, bypassing damaged complexes I and III to support ATP production — a mechanism that has generated real interest in the biohacking and longevity community for cognitive and energy effects. Low-dose use is the operative phrase here: the dose-response curve is U-shaped, meaning higher amounts that help in animal models of disease can become pro-oxidant and harmful, and only pharmaceutical-grade (USP) methylene blue, not aquarium or industrial-grade product, should ever be considered. It also inhibits MAO enzymes, creating a serious interaction risk with serotonergic drugs and supplements.
Effects
First dose
subtle cognitive lift for some within hours
Same day
dose and source purity matter enormously
Caution
only pharmaceutical-grade USP is appropriate
How it Feels
At genuinely low doses some report a mild cognitive or energy lift within hours; it also famously turns urine blue-green, which is expected. Purity is critical, so only pharmaceutical USP grade is appropriate, and it must never be combined with serotonergic medications. This is a compound to approach carefully and with guidance.
Usage
Entry Dose
0.5mg/kg (research range, low-dose)
Standard Dose
1mg/kg (research range, low-dose)
Max Dose
Use only under guidance; high doses are toxic
Onset
Hours (cognitive); requires pharmaceutical-grade USP source
Combinations
Pairs well with
Synergistic
CoQ10 — complementary mitochondrial electron transport support
PQQ — both support mitochondrial bioenergetics through distinct mechanisms
Avoid combining
Contraindicated
SSRIs, SNRIs, MAOIs, or any serotonergic supplement (5-HTP, St. John's Wort) — serious serotonin syndrome risk via MAO inhibition
G6PD deficiency — risk of hemolytic anemia
Non-pharmaceutical-grade product — industrial/aquarium-grade methylene blue contains contaminants unsafe for ingestion
Pregnancy — contraindicated
Biomarkers to Track
Subjective
(Daily)
Mental clarity and focus (1–10)
Energy levels
Urine color change (expected, harmless blue-green tint)
Objective
(Quarterly)
G6PD screening (before first use)
Methemoglobin level (if monitoring clinically)
Cognitive testing battery (reaction time, working memory)
Has MAOI-like activity, so combined with serotonergic drugs it can cause dangerous serotonin syndrome. Only pharmaceutical USP grade is appropriate.
Anyone on antidepressants or serotonergic drugs, and people with G6PD deficiency.
Using non-pharmaceutical grade, dosing too high, and combining it with SSRIs.
Preliminary (limited / small human data)
This is one small acute imaging study, not a body of clinical outcome trials. Methylene blue has MAOI-like serotonergic activity and can cause dangerous interactions with SSRIs, SNRIs, and other serotonergic drugs; broad nootropic, mitochondrial, and longevity claims substantially outrun the human evidence.
Rodriguez P et al. (2016). Radiology, 281(1), 516-526. RCT (low-dose methylene blue, fMRI memory/attention, n=26). PMID: 27379190. DOI: 10.1148/radiol.2016152893.